TEATROIS

This brand name is authorized in Estonia, France.

Active ingredients

The drug TEATROIS contains one active pharmaceutical ingredient (API):

`1`	Tiratricol UNII `29OQ9EU4R1` - TIRATRICOL
	Tiratricol (3,3',5-triiodothyroacetic acid) is a naturally circulating metabolite of active thyroid hormone (T3) with a high degree of structural similarity and follows the same downward degradation pathway (deiodination and conjugation) and elimination via bile and urine. Tiratricol has been demonstrated to be able to enter MCT8 dependent cells without a functioning MCT8 transporter unlike T3 and T4. Tiratricol can thereby replace T3 in MCT8 dependent tissues and restore normal thyroid hormone activity across tissues.
	Read more about Tiratricol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H03AA04	Tiratricol	H Systemic hormonal preparations, excl. Sex hormones and insulins → H03 Thyroid therapy → H03A Thyroid preparations → H03AA Thyroid hormones
Discover more medicines within H03AA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1735646, 1737110
FR	Base de données publique des médicaments	63030409

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.